Personalis Inc (PSNL) Stock Price, Quote & News

Company Profile

Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD), therapy response and recurrence monitoring in solid tumor cancers; and ImmunoID NeXT, a tissue-based service that combines whole exome and whole transcriptome sequencing data with advanced analytics to provide a multi-dimensional view of the tumor an...

Industry: Diagnostics & Research

Sector: Healthcare

Phone: 650 752 1300

Fax: 650 752 1301

Website: www.personalis.com

Address:

6600 Dumbarton Circle, Fremont, United States

LiquidThetaLEAPS Oct. 4 at 7:54 PM

LiquidTheta® LEAPS LIVE Actionable Alert Asset: $PSNL Current Share Price: $7.34 Contracts: $PSNL April 17, 2026 $8 Calls Scale in: $1.96- $2.40 Scale out: $3.05-$3.92 Can Easily Capture: 60% ROI Blended DTE: 196 Days | Join Elites here: https://liquidtheta.com/options

0 · Reply

NeverFadeTheOracle Oct. 3 at 6:48 PM

$PSNL Cancer play

0 · Reply

marcopol0 Oct. 3 at 6:19 PM

$PSNL can’t keep it down 😂

0 · Reply

LordBrypto Oct. 3 at 5:11 PM

$PSNL news over the weekend ?

0 · Reply

Wax_Bean_futures Oct. 3 at 4:58 PM

$PSNL somebody knows something

0 · Reply

Universaal Oct. 3 at 4:46 PM

$PSNL should have been $50 dollars this is cancer detection not sure when market will notice that?

0 · Reply

LukasWo Oct. 3 at 4:06 PM

$PSNL nice price action and volume so far today. Could it be today? Or some time next week?

1 · Reply

LordBrypto Oct. 3 at 3:51 PM

$PSNL $25

1 · Reply

BioTechNoir Oct. 3 at 3:47 PM

$PSNL $11

0 · Reply

Tejj Oct. 3 at 3:44 PM

$PSNL shit, didnt give me time to add.

0 · Reply

Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep 10, 2025, 4:05 PM EDT - 24 days ago

CATE Clinical Trial Launched to Demonstrate the Clinical Utility of ctDNA-Guided Treatment in Breast Cancer Using the Ultrasensitive NeXT Personal Test

Sep 3, 2025, 4:05 PM EDT - 4 weeks ago

Personalis Announces New Data from a Landmark Neoadjuvant Lung Cancer Trial Showing Superiority of Ultra-Sensitive, Tumor-Informed MRD Testing

Aug 27, 2025, 4:01 PM EDT - 5 weeks ago

Personalis to Participate in Upcoming Investor Conferences

Aug 6, 2025, 8:11 AM EDT - 2 months ago

Super Micro Computer Posts Downbeat Q4 Results, Joins Personalis, Snap And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

SMCI

Aug 5, 2025, 10:49 PM EDT - 2 months ago

Personalis, Inc. (PSNL) Q2 2025 Earnings Call Transcript

Aug 5, 2025, 4:01 PM EDT - 2 months ago

Personalis Reports Second Quarter 2025 Financial Results

Jul 22, 2025, 4:01 PM EDT - 2 months ago

Personalis to Announce Second Quarter 2025 Financial Results

Jul 9, 2025, 4:00 PM EDT - 3 months ago

Personalis Expands Tempus Strategic Collaboration to Bring Ultra-Sensitive Cancer Recurrence Testing to Colorectal Cancer Patients

TEM

Jun 3, 2025, 4:00 PM EDT - 4 months ago

Personalis' NeXT Personal® Predicts Cervical Cancer Recurrence Risk in New CALLA Phase 3 Study Analysis Presented at ASCO

Jun 2, 2025, 4:00 PM EDT - 4 months ago

New Data Shows NeXT Personal® Identifies Breast Cancer Patients Receiving Neoadjuvant Therapy that are at High Risk for Relapse

May 22, 2025, 6:00 AM EDT - 4 months ago

Personalis and Academic Partners to Present Latest Data on Ultrasensitive ctDNA Assay for Residual Cancer and Recurrence Detection

May 14, 2025, 4:01 PM EDT - 5 months ago

Personalis to Participate at the Craig-Hallum 22nd Annual Investor Conference

May 6, 2025, 8:41 PM EDT - 5 months ago

Personalis, Inc. (PSNL) Q1 2025 Earnings Call Transcript

May 6, 2025, 4:01 PM EDT - 5 months ago

Personalis Reports First Quarter 2025 Financial Results

Apr 28, 2025, 5:00 PM EDT - 5 months ago

Personalis' NeXT Personal® Detects 100% of Colorectal Cancer Relapses Ahead of Imaging in VICTORI Cancer Study

Apr 22, 2025, 4:01 PM EDT - 5 months ago

Personalis to Announce First Quarter 2025 Financial Results

Apr 22, 2025, 6:00 AM EDT - 5 months ago

Personalis and Academic Partners to Present Latest Data on Ultrasensitive ctDNA Test for Residual Cancer and Recurrence Detection

Mar 26, 2025, 4:01 PM EDT - 6 months ago

Personalis to Participate at the 24th Annual Needham Virtual Healthcare Conference

Mar 3, 2025, 6:00 AM EST - 7 months ago

New Publication from ICR and Royal Marsden Researchers Highlights the Importance of Ultra-Sensitive ctDNA Testing for Early-Stage Breast Cancer Recurrence Detection

Feb 27, 2025, 7:40 PM EST - 7 months ago

Personalis, Inc. (PSNL) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 4:01 PM EST - 7 months ago

Personalis Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 21, 2025, 4:21 PM EST - 8 months ago

3 Biotech/Healthcare Names Under $10 I Am Buying Now

ARDX GERN MRNA TEM

Feb 18, 2025, 4:01 PM EST - 8 months ago

Personalis to Participate at the TD Cowen's 45th Annual Health Care Conference

Feb 14, 2025, 10:50 AM EST - 8 months ago

Exciting Technology At Personalis, But Profitability Eludes Them

Feb 13, 2025, 4:01 PM EST - 8 months ago

Personalis to Announce Fourth Quarter and Full Year 2024 Financial Results

Jan 28, 2025, 4:01 PM EST - 8 months ago

Personalis to Participate at the BTIG Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Jan 13, 2025, 5:00 AM EST - 9 months ago

New Nature Medicine Publication Shows ctDNA Levels Linked to Recurrence Risk in Lung Cancer

Jan 7, 2025, 4:01 PM EST - 9 months ago

Personalis Reports Preliminary Fourth Quarter and Full Year 2024 Revenue

Dec 19, 2024, 9:00 AM EST - 10 months ago

Personalis Advances Business Strategy with Investment from Merck and Extends Collaboration with Moderna

Dec 16, 2024, 8:00 AM EST - 10 months ago

Personalis and Tempus Expand Collaboration to Biopharma

TEM

Nov 20, 2024, 4:01 PM EST - 11 months ago

Personalis to Participate at Upcoming Investor Conferences

Nov 6, 2024, 8:11 PM EST - 11 months ago

Personalis, Inc. (PSNL) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 4:01 PM EST - 11 months ago

Personalis Reports Third Quarter 2024 Financial Results

Nov 5, 2024, 4:01 PM EST - 11 months ago

Personalis to Present at the Stifel 2024 Healthcare Conference

Oct 23, 2024, 4:01 PM EDT - 1 year ago

Personalis to Announce Third Quarter 2024 Financial Results

Sep 16, 2024, 9:00 AM EDT - 1 year ago

ESMO 2024 Data Expands on Compelling Performance of Personalis NeXT Personal® MRD Test

Aug 18, 2024, 7:47 AM EDT - 1 year ago

Personalis: Resetting My Strategy Following The Q2 Beat

Aug 16, 2024, 8:30 AM EDT - 1 year ago

Personalis and Tempus Announce Expanded Collaboration

TEM

Aug 7, 2024, 11:09 PM EDT - 1 year ago

Personalis, Inc. (PSNL) Q2 2024 Earnings Call Transcript

Aug 7, 2024, 4:01 PM EDT - 1 year ago

Personalis Reports Second Quarter 2024 Financial Results

Jul 31, 2024, 4:01 PM EDT - 1 year ago

Personalis to Participate at the 9th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference

Jul 24, 2024, 4:01 PM EDT - 1 year ago

Personalis to Announce Second Quarter 2024 Financial Results

Jun 18, 2024, 4:01 PM EDT - 1 year ago

Personalis to Participate at the TD Cowen 3rd Annual Tools / Dx Revolution Conference

Jun 13, 2024, 8:00 AM EDT - 1 year ago

Personalis Provides Dial-in and Updated Date for ASCO Highlights Conference Call

Jun 4, 2024, 4:05 PM EDT - 1 year ago

ASCO Data Highlights NeXT Personal® Ultra-sensitive MRD Performance in Early-stage Breast Cancer Recurrence Detection and Immunotherapy Monitoring

May 31, 2024, 9:05 AM EDT - 1 year ago

Personalis Announces Start of Cancer MRD Testing Commercialization Collaboration with Tempus

May 22, 2024, 9:05 AM EDT - 1 year ago

Personalis Announces Podium Presentations and Abstracts Accepted at ASCO 2024

May 22, 2024, 9:00 AM EDT - 1 year ago

Antares Bolsters Private Wealth Team with Three New Senior Appointments

KHC

May 8, 2024, 11:53 PM EDT - 1 year ago

Personalis, Inc. (PSNL) Q1 2024 Earnings Call Transcript

LiquidThetaLEAPS Oct. 4 at 7:54 PM

0 · Reply

NeverFadeTheOracle Oct. 3 at 6:48 PM

$PSNL Cancer play

0 · Reply

marcopol0 Oct. 3 at 6:19 PM

$PSNL can’t keep it down 😂

0 · Reply

LordBrypto Oct. 3 at 5:11 PM

$PSNL news over the weekend ?

0 · Reply

Wax_Bean_futures Oct. 3 at 4:58 PM

$PSNL somebody knows something

0 · Reply

Universaal Oct. 3 at 4:46 PM

$PSNL should have been $50 dollars this is cancer detection not sure when market will notice that?

0 · Reply

LukasWo Oct. 3 at 4:06 PM

$PSNL nice price action and volume so far today. Could it be today? Or some time next week?

1 · Reply

LordBrypto Oct. 3 at 3:51 PM

$PSNL $25

1 · Reply

BioTechNoir Oct. 3 at 3:47 PM

$PSNL $11

0 · Reply

Tejj Oct. 3 at 3:44 PM

$PSNL shit, didnt give me time to add.

0 · Reply

Albino_Trader123 Oct. 3 at 3:40 PM

$PSNL incredible weekly and daily looking chart

0 · Reply

degeneratetrader23 Oct. 3 at 3:03 PM

$PSNL its happening, isnt it?

0 · Reply

Penki1985 Oct. 3 at 3:01 PM

$PSNL

0 · Reply

BioTechNoir Oct. 3 at 2:49 PM

$PSNL SEND IT

0 · Reply

arribaStocktrading Oct. 3 at 2:14 PM

$PSNL Here's a thought. Maybe we could hold 7 today? And another thing... The rotation into Small Caps has been fantasy fiction for a very long time and it wouldn't hurt to feed us more than a few breadcrumbs.... we deserve a steak for our long-term suffering. Give that man a steak. STEAK! STEAK! STEAK! STEAK!

0 · Reply

degeneratetrader23 Oct. 3 at 2:01 PM

$PSNL looks like yesterday where we spike to 7.07 and drift lower? Or....

0 · Reply

LordBrypto Oct. 3 at 11:00 AM

$PSNL here comes the boom

0 · Reply

Universaal Oct. 3 at 3:21 AM

$PSNL thinking to sell and move to $SRPT for good enough of this snail 🐌 move seems garbage

3 · Reply

BioTechNoir Oct. 2 at 9:37 PM

$PSNL

0 · Reply

Wax_Bean_futures Oct. 2 at 6:49 PM

$PSNL Well, at least my $PRME is up 16% today

1 · Reply

LiquidThetaLEAPS Oct. 2 at 5:36 PM

LiquidTheta® LEAPS LIVE Actionable Alert Asset: $PSNL Current Share Price: $6.91 Contracts: $PSNL April 17, 2026 $8 Calls Scale in: $1.89- $2.31 Scale out: $2.94-$3.78 Can Easily Capture: 60% ROI Blended DTE: 198 Days | Join Elites here: https://liquidtheta.com/options

0 · Reply

Universaal Oct. 2 at 4:39 PM

$PSNL is this done?? Tired of this snail stock looking like no growth

2 · Reply

Market Cap	650.89M
Revenue (ttm)	84.61M
Net Income (ttm)	-81.28M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-96.06%
Debt to Equity Ratio	0.00

Volume	1,310,800
Avg Vol	969,356
Day's Range	N/A - N/A
Shares Out	88.68M
Stochastic %K	96%
Beta	1.83
Analysts	Strong Sell
Price Target	$7.19